Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part B (Q40350655)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 1, 1975

Language	Label	Description	Also known as
English	Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part B	scientific article published on November 1, 1975

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part B (English)

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

electrophysiology

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

author name string

A. L. Wit

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:242208

7 June 2022

B. F. Hoffman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:242208

7 June 2022

M. R. Rosen

0 references

language of work or name

0 references

publication date

1 November 1975

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:0002870375902318?httpAccept=text/xml

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

https://api.elsevier.com/content/article/PII:0002870375902318?httpAccept=text/plain

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

90

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

665-675

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

The use of beta-adrenergic receptor blocking drugs in dysrhythmias

4

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Propranolol treatment of chronic intractable supraventricular arrhythmias

5

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Practolol in treatment of supraventricular cardiac dysrhythmias

6

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Immediate effects of intravenous propranolol on various cardiac arrhythmias.

8

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Control of persistent ventricular ectopic beats by alprenolol, a new beta-adrenergic blocking agent

9

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Use of a beta adrenergic receptor blocking agent (propranolol) in the treatment of cardiac arrhythmias

11

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Acute and chronic effects of an adrenergic beta-receptor blocking agent (propranolol) in treatment of cardiac arrhythmias

12

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Clinical observations on the use of propranolol in disorders of cardiac rhythm

13

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Clinical use of I.C.I. 50172 as an antidysrhythmic agent in heart failure

16

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias.

18

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Rapidly recurring supraventricular tachycardia. A manifestation of reciprocating tachycardia and an indication for propranolol therapy

19

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Treatment of cardiac arrhythmias in unanesthetized patients. Role of adrenergic beta receptor blockade.

20

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Effect of Sotalol on clinical arrhythmias.

21

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Long term treatment of paroxysmal cardiac arrhythmias with propranolol.

22

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Propranolol in the Treatment and Prevention of Cardiac Arrhythmias

23

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

The use of propranolol in arrhythmias complicating acute myocardial infarction

24

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Practolol in the treatment of cardiac dysrhythmias due to acute myocardial infarction

25

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Use of alprenolol in acute cardiac arrhythmias.

26

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Propranolol in the treatment of digitalis-induced and digitalis-resistant tachycardias

27

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

The use of practolol in supraventricular arrhythmias associated with acute illnesses

28

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

The effect of the dextro isomer of propranolol on sinus rate and cardiac arrhythmias

29

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Action of propranolol on the atrioventricular node and on its response to adrenaline and isoprenaline

30

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Effects of propranolol and ouabain on the conducting system of the heart in dogs

31

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Post-countershock arrhythmias in untreated and digitalized dogs.

32

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Cardiac Sympathetic Nerve Activity: Changes Induced by Ouabain and Propranolol

33

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Q-T interval syndromes

34

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

The surdo-cardiac syndrome and therapeutic observations

35

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Heritable Q-T Prolongation Without Deafness

36

0 references

Epinephrine-Cyclopropane Effects on Purkinje Fibers

37

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Absence of prophylactic effect of propranolol in myocardial infarction

40

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Beta-adrenergic blockade in cardiac infarction

41

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Combined propranolol and quinidine treatment in cardiac arrhythmias

42

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment

43

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Clinical usefulness of beta-adrenergic blocking agents

45

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.

46

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Clinical pharmacology of propranolol

47

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man

48

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Effect of route of administration on the relationship between -adrenergic blockade and plasma propranolol level.

49

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Relation of propranolol plasma level to beta-blockade during oral therapy

50

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol

51

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Plasma Propranolol Levels Associated with Suppression of Ventricular Ectopic Beats

52

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Plasma propranolol levels in adults With observations in four children

53

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

54

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

The disposition of propranolol. I. Elimination during oral absorption in man

55

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Isopropylamine, a biologically active deamination product of propranolol in dogs: identification of deuterated and unlabeled isopropylamine by gas chromatography-mass spectrometry

57

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites

58

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol

59

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Central nervous system effects and metabolic disposition of a glycol metabolite of propranolol

62

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.

63

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol

64

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Pharmacodynamics of Propranolol in Renal Failure

65

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Pharmacokinetics of oral propranolol in chronic renal disease

66

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man

68

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.

69

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Correlation of beta blockade with serum practolol levels after oral administration

70

1 reference

10.1016/0002-8703(75)90231-8

https://api.crossref.org/works/10.1016/0002-8703(75)90231-8

7 June 2022

Identifiers

10.1016/0002-8703(75)90231-8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40350655&oldid=1820202831"